Growth hormone's ability to burn fat has been documented for decades. The challenge has always been that full GH administration brings a set of metabolic consequences — elevated IGF-1, insulin resistance, fluid retention, cell proliferation signals — that are undesirable when fat loss is the sole objective.
Fragment 176-191 is the most direct attempt to isolate GH's fat-burning signal from everything else. It is a 16-amino-acid peptide corresponding to the C-terminal end of human growth hormone — specifically amino acids 176 through 191 of the hGH sequence — the region that research identified as responsible for GH's lipolytic activity.
Understanding Fragment 176-191 requires understanding its relationship to AOD-9604, the metabolic pathways it targets, the actual scope of its human research base, and why its use context in 2025 is fundamentally different from how it was discussed a decade ago.
⚠️ Important Disclaimer: Fragment 176-191 is an investigational research peptide with no FDA approval for human use. This article is for educational purposes only and does not constitute medical advice.
What Is Fragment 176-191?
Fragment 176-191 is the C-terminal segment of the 191-amino-acid human growth hormone molecule, comprising residues 176 through 191. Unlike AOD-9604 — which adds a tyrosine residue at position 177 for molecular stability — Fragment 176-191 is the unmodified natural sequence of this region, exactly as it appears in native GH.
The distinction between Fragment 176-191 and AOD-9604 is subtle but important:
| Feature | Fragment 176-191 | AOD-9604 |
|---|---|---|
| Sequence | Amino acids 176–191 of hGH — unmodified | Amino acids 177–191 with added N-terminal tyrosine |
| Molecular stability | Lower — natural sequence is more susceptible to enzymatic degradation | Higher — tyrosine modification improves stability |
| Clinical trial history | No human Phase 2/3 trials | Phase 2 and Phase 3 trials conducted |
| FDA GRAS status | No | Yes (2014) |
| Research depth | Primarily preclinical (animal and in vitro) | Preclinical + human clinical trials |
| Community use prevalence | Very common — often used interchangeably with AOD-9604 | Common |
In research peptide communities, Fragment 176-191 and AOD-9604 are frequently discussed as if they are the same compound. They are not — though their mechanisms overlap substantially, and the practical difference in real-world use is often minimal given that both are purchased from unregulated suppliers where exact sequence verification is rarely possible.
How Does Fragment 176-191 Work?
The mechanism is essentially the same as AOD-9604 — both target GH's fat-specific metabolic pathway through the same C-terminal region of the molecule.
Lipolysis Stimulation
Fragment 176-191 stimulates the breakdown of stored triglycerides in adipocytes into free fatty acids. The proposed mechanism involves activation of beta-3 adrenergic-like signaling in fat cells — mimicking a subset of GH's fat cell receptor interactions without requiring the full GH molecule or engagement of the GH receptor complex that drives IGF-1 production and anabolic effects.
Lipogenesis Inhibition
In parallel with stimulating fat breakdown, Fragment 176-191 inhibits the formation of new fat from dietary carbohydrates and excess calories. This dual action — enhanced lipolysis plus reduced lipogenesis — is the same two-pronged mechanism identified in AOD-9604 research.
No IGF-1, No Insulin Effects
Critically — and this is the defining property of both Fragment 176-191 and AOD-9604 — the C-terminal fragment does not bind the GH receptor complex in a way that stimulates IGF-1 production. It does not produce insulin resistance, does not suppress endogenous GH secretion, and does not drive cell proliferation. The fat-burning signal is functionally isolated from GH's growth-promoting and metabolic side effects.
What the Research Actually Shows
This is where intellectual honesty is essential. Fragment 176-191's research base is almost entirely preclinical — animal studies and in vitro work. Unlike AOD-9604, it has not been taken through human Phase 2 or Phase 3 clinical trials. Everything known about its effects in humans comes from the extrapolation of animal data and community use reports.
Animal Studies
The preclinical evidence is consistent:
- Obese rodent models treated with Fragment 176-191 show reductions in body fat percentage compared to controls
- No effects on blood glucose or insulin sensitivity in treated animals
- No effects on IGF-1 levels or linear growth in young animals
- Fat-specific activity confirmed — reductions in adipose tissue without changes in lean mass
(View related studies on PubMed)
The Translation Problem
The important caveat is that AOD-9604 — the more stable, modified version of essentially the same sequence — did not produce statistically significant weight loss in Phase 3 human trials at doses tested. This is the most relevant piece of human-proximate data for Fragment 176-191, and it suggests that the fat loss magnitude seen in rodents does not translate straightforwardly to clinically meaningful outcomes in humans at practical peptide doses.
This does not mean Fragment 176-191 has no activity in humans. It means the effect size in humans is likely modest when used as a standalone agent — consistent with the AOD-9604 Phase 3 experience.
No Human Clinical Trial Data
There are no published human Phase 1, Phase 2, or Phase 3 trials specifically for Fragment 176-191. All mechanistic claims about its effects in humans are extrapolated from animal research and the AOD-9604 clinical program. This is a meaningful limitation that distinguishes Fragment 176-191 from most other compounds discussed in this series.
Effects: What Users and Research Report
1. Targeted Fat Mobilization
The most consistently reported effect in both animal research and community use: preferential mobilization of stored fat — particularly from subcutaneous fat depots — without the metabolic side effects of full GH administration. Whether the magnitude of this effect is clinically meaningful as a standalone intervention in humans remains unconfirmed by clinical trial data.
2. No Metabolic Disruption
The absence of insulin resistance, IGF-1 elevation, and glucose effects is a genuine and well-documented property. For users who want to add a fat-metabolism signal to their protocol without the glucose and hormonal baggage of GH secretagogues, Fragment 176-191 offers a pharmacologically clean option — even if the fat loss magnitude is modest.
3. Potential Complementary Role in GH Secretagogue Stacks
The most rational current use case: as a component of a broader GH optimization protocol, where Fragment 176-191 adds targeted fat cell signaling without compounding the metabolic burden of the GH secretagogue stack. Whether this additive effect is pharmacologically meaningful in practice is not established by controlled trial data.
4. Body Composition During Caloric Restriction
Some users report that Fragment 176-191, when used during a caloric deficit, appears to preferentially preserve lean mass while accelerating fat loss — consistent with the animal data showing fat-specific activity without lean tissue effects. This is plausible given the mechanism but not confirmed in human trials.
Dosage and Protocol
The following reflects commonly discussed research protocols. This is not medical advice.
| Parameter | Details |
|---|---|
| Typical dose | 200–500 mcg per injection |
| Route | Subcutaneous injection — abdominal fat preferred |
| Frequency | Once daily, or twice daily for more intensive protocols |
| Timing | Fasted state — morning before eating, or pre-workout fasted. Insulin blunts the lipolytic signal; always administer away from meals. |
| Cycle length | 4–12 weeks; many users run it continuously during fat loss phases |
Common Stack Combinations
| Stack Partner | Rationale | Context |
|---|---|---|
| CJC-1295 w/o DAC + Ipamorelin | GH secretagogue stack provides systemic GH/IGF-1 optimization; Fragment 176-191 adds targeted lipolytic signal without IGF-1 compounding | Body recomposition — lean mass preservation with fat loss emphasis |
| Tesamorelin | Tesamorelin drives visceral fat reduction through GH axis; Fragment 176-191 targets subcutaneous fat through the fragment pathway — potentially complementary depots | Aggressive fat loss protocol |
| AOD-9604 | Overlapping mechanism — questionable whether stacking both adds meaningful benefit over using one at a higher dose | Not generally recommended due to mechanism overlap |
| 5-Amino-1MQ | 5-Amino-1MQ targets NNMT enzyme inhibition for metabolic rate upregulation; Fragment 176-191 targets adipocyte lipolysis directly — different mechanisms | Metabolic optimization stack |
Side Effects and Safety
Fragment 176-191 has a favorable reported safety profile — consistent with its mechanism, which deliberately avoids the receptor interactions responsible for GH's metabolic side effects.
Reported Side Effects
- Mild injection site redness or irritation — the most commonly reported adverse effect
- Mild flushing or warmth after injection in some users
- Occasional headache, particularly in the first days of use
- Rare reports of mild nausea at higher doses (above 500 mcg)
- Dizziness or lightheadedness immediately post-injection in sensitive individuals
What Is Not Expected
- No water retention or edema — this effect is linked to IGF-1, which Fragment 176-191 does not elevate
- No fasting glucose elevation or insulin resistance
- No cortisol or prolactin changes
- No suppression of endogenous GH production
- No IGF-1 elevation — confirmed in animal studies and consistent with the mechanism
Malignancy Consideration
Unlike full GH or GH secretagogues, Fragment 176-191 does not stimulate IGF-1 or cell proliferation pathways. The primary mechanism by which GH-related compounds raise theoretical oncological concern — sustained IGF-1 elevation — is absent. The compound should still be used with physician oversight in anyone with a cancer history, but it does not carry the same IGF-1-related concern as GH secretagogue protocols.
How to Reconstitute Fragment 176-191
- Use bacteriostatic water for reconstitution and preservation.
- Inject bacteriostatic water slowly into the vial along the inside wall.
- Gently swirl until fully dissolved. Do not shake.
- Store the reconstituted vial in the refrigerator (2–8°C). Do not freeze after reconstitution.
- Reconstituted Fragment 176-191 is typically stable for 4–6 weeks under refrigeration.
Fragment 176-191 vs. AOD-9604: Which Should You Use?
This is the most practically relevant question for anyone considering either compound. The honest answer:
- AOD-9604 has more evidence behind it — it went through Phase 2 and Phase 3 human trials, has a GRAS designation, and has a more stable molecular structure due to the tyrosine modification
- Fragment 176-191 is more widely available and less expensive — it is the more commonly sold compound in research peptide markets, despite having less human data
- Their mechanisms are functionally equivalent — both target the same C-terminal GH fat-burning region through the same lipolytic pathway
- Neither has demonstrated robust standalone fat loss in humans — the AOD-9604 Phase 3 failure is the relevant benchmark for both
If forced to choose between them strictly on evidence quality, AOD-9604 is the more defensible option due to its clinical trial history. In practice, most users choose based on price and availability — Fragment 176-191 is typically more accessible — accepting that the mechanistic difference is unlikely to be pharmacologically decisive at research peptide doses.
Frequently Asked Questions
Does Fragment 176-191 actually burn fat?
It has documented lipolytic activity in animal research — consistent and repeated across multiple studies. Whether the magnitude of this effect in humans at practical doses is clinically meaningful as a standalone agent is questionable based on the AOD-9604 Phase 3 experience. Most practitioners view it as a potentially useful component of a broader fat loss protocol rather than a primary driver of fat loss on its own.
Is Fragment 176-191 the same as HGH Fragment?
Yes — "HGH Fragment," "HGH Fragment 176-191," and "Fragment 176-191" all refer to the same compound. These names are used interchangeably across research peptide vendors and community discussions.
Can Fragment 176-191 be used without a caloric deficit?
Its mechanism involves stimulating fat cell lipolysis — mobilizing stored fat into the circulation for energy. If that mobilized fat is not burned through energy expenditure exceeding intake, it will simply be reesterified and returned to storage. A caloric deficit and regular physical activity are necessary contexts for Fragment 176-191's lipolytic effects to translate into actual fat mass reduction.
How does Fragment 176-191 compare to GLP-1 agonists for fat loss?
There is no meaningful comparison. GLP-1 agonists like Semaglutide and Tirzepatide produce average weight loss of 15–22% in Phase 3 trials with thousands of participants. Fragment 176-191 has no Phase 3 human trial data, and the closest proxy — AOD-9604 — did not demonstrate significant standalone fat loss at that clinical scale. GLP-1 agonists are categorically more potent fat loss agents when used under appropriate medical supervision. Fragment 176-191 is most relevant to users already using GH secretagogues who want to add a targeted fat metabolism component without IGF-1 or insulin effects.
Is Fragment 176-191 detectable in anti-doping tests?
GH fragments including Fragment 176-191 are on the WADA prohibited list as GH-related peptides. Athletes subject to anti-doping testing should treat Fragment 176-191 as prohibited and verify its status in the specific anti-doping rules applicable to their sport.
What is the difference between Fragment 176-191 and Fragment 177-191?
"Fragment 177-191" sometimes appears in vendor listings. It typically refers to the same compound — the numbering variation reflects different conventions for counting the amino acid positions. In practice, the compounds being sold are functionally the same C-terminal GH fragment region. Product quality, sequence accuracy, and purity from unregulated suppliers are the more practically significant variables than the numbering convention.
Where to Learn More
- Growth hormone fragment 176-191 research on PubMed
- AOD-9604 clinical research on PubMed — relevant proxy data
- WADA Prohibited List — verify anti-doping status
For research-based posts on every major fat loss peptide and metabolic compound — from GH fragments and GLP-1 agonists to Adipotide and 5-Amino-1MQ — visit our resource library.
The Bottom Line
Fragment 176-191 is mechanistically elegant and practically clean — a peptide that targets fat cell lipolysis through the same C-terminal GH sequence that drove decades of growth hormone fat-burning research, without the insulin, IGF-1, and cell proliferation consequences that make full GH administration problematic.
Its limitation is the same as AOD-9604's: the fat loss magnitude it produces as a standalone agent in humans appears to be modest, based on the most relevant available data. Used as part of a broader fat loss protocol — in the context of a caloric deficit, resistance training, and potentially combined with GH secretagogues for complementary mechanisms — it represents a pharmacologically rational addition with an excellent safety profile.
The next post in this series covers Adipotide — an entirely different approach to fat loss through a mechanism that has no parallel in the peptide world: targeted destruction of the blood supply to fat tissue. Stay tuned.
